Reagents

anti-Mouse IgG h+l Antibody (Goat) - FITC Conjugated

Catalog #
GGHL-90F
Product Size
1.0 mg
$92.97
More Information
Antibody Type Secondary Antibody
Host Goat
Target Species Mouse
Specificity/Target Mouse IgG h+l
Size 1.0
Clonality Polyclonal
Type FITC Conjugated
Isotype IgG
Origin USA
Shelf Life 1 year
Format Liquid
Buffer Phosphate buffered saline (PBS), pH 7.2 with 0.2% BSA
Preservative 0.09% sodium azide
Storage 2-8C
Application ELISA
Purity Antigen Affinity Purified
Data Sheet
PP_GGHL-90F.pdf
SDS
ICL_SDS_GGHL-90F.pdf

Product Citations for ICL's FITC Conjugated Goat anti-Mouse IgG h+l:

Gorczynski RM et al. Effect of infusion of monoclonal antibodies to tumour necrosis factor‐receptor super family 25 on graft rejection in allo‐immune mice receiving autologous marrow transplantation Immunology. 2017 Apr; 150(4): 418–431

Urbanellis P, Shyu W, Khattar R, et al. The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts. Immunology. 2015;144(1):91-106. doi:10.1111/imm.12354

Zhang JT et al. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway BMC Cancer 201414:193 DOI: 10.1186/1471-2407-14-193

Lu XS et al. Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas International Journal of Oncology Pages: 2103-2115 DOI: 10.3892/ijo.2013.1897

Zhao Y et al. Proteomic analysis of primary duck hepatocytes infected with duck hepatitis B virus Proteome Science20108:28 DOI: 10.1186/1477-5956-8-28

Xu H et al. Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization March 15, 2008; Blood: 111 (6)

View product citations for GGHL-90F on CiteAb
Publishing research using our antibodies or ELISA kits? TELL US AND RECEIVE A $150 COUPON
All Content ICL, Inc. All Rights Reserved